Cell death is an integral part of the life of an organism being necessary for the maintenance of organs and tissues. If, however, cell 
Introduction

Cell death and pathophysiology
Cell death is a crucial process in the development of an organism and in the maintenance of tissue integrity through the elimination of redundant or damaged cells [1] . Apart from its role in normal cellular processing, however, cell death is known to make substantial contributions to a variety of pathological conditions including cancer [2] , neurodegenerative disorders [3] , autoimmune diseases [4] and ischemia-reperfusion (I/R) injury [5] . In a recent report from the Nomenclature Committee on Cell Death [6] [7] .
Apoptosis
Apoptosis, type-I (active) cell death or, as it was originally known, 'shrinkage necrosis' [8] is a genetically programmed mechanism that is associated with the activation of cysteine-dependent aspartate-specific proteases called caspases and is involved in development and homeostasis [9] . The term apoptosis was originally coined by Kerr and colleagues who focused on the specific morphological features that develop during the course of this process [8, 10] . Apoptotic cell death is characterized by rounding up of the cell, cellular shrinkage, plasma membrane blebbing, pseudopod retraction, chromatin condensation and DNA degradation, and ultimately phagocytosis.
Autophagy
Autophagy or type-II cell death takes three forms, macroautophagy [11, 12] , microautophagy [13] and chaperone-mediated autophagy [14] . [15] [16] [17] . Importantly, unlike apoptosis and necrosis, autophagy is essentially a survival mechanism that is activated in response to stress such as starvation, hypoxia, mitochondrial dysfunction and infection [18, 19] . It promotes tissue survival by generating amino acids and fatty acids necessary for maintaining normal cellular function during times of nutrient deficiency, or by removing damaged organelles and intracellular pathogens [20] . Autophagy may, however, promote cell death if uncontrolled leading to excessive degradation of cellular components and the development of pathological conditions [21] . It has been reported that interactions may occur between the ubiquitin-proteasome system, which is the principal non-lysosomal system responsible for the degradation of normal and abnormal intracellular proteins [22] and apoptosis [23] . Interactions between autophagic and apoptotic pathways have also been observed [24, 25] 
It is a bulk degradation mechanism which is involved in the dismantling of normal and aggregated proteins, and organelles, including mitochondria. Macroautophagy, which predominates in mammalian cells, is associated with the sequestration of cellular components by double-membrane enclosed vesicles, termed autophagosomes, which then fuse with lysosomes to form autolysosomes where proteolytic degradation occurs
Necroptosis
Necroptosis is a newly identified type of cell death that has attracted considerable attention over the last few years and been suggested to represent a form of programmed necrosis or regulated nonapoptotic cell death [34] . It was originally described by Degterev et al. [7] , although it should be noted that Formigli et al. [35] previously reported on a phenomenon which shares dynamic, molecular and morphological features with apoptosis and necrosis, which they named aponecrosis. In their study, Degterev and coworkers [7] [7] . Necroptosis was found to occur normally when cells were challenged with the inhibitor of autophagy, 3-methyladenine, and it was concluded that autophagy occurred downstream of necroptosis, rather than contributing to its development. In another study [36] [38] .
Using obatoclax, a putative inhibitor of members of the BCL-2 family, it was demonstrated that glucocorticoid resistance was reversed in childhood acute lymphoblastic leukaemia cells through activation of autophagy-dependent necroptosis, a mechanism which bypassed the block in mitochondrial apoptosis characteristic of this condition. The induction of cell death was associated with the dissociation of beclin-1 from the anti-apoptotic BCL-2 family member myeloid cell leukaemia sequence 1 and a reduction in mammalian target of rapamycin (mTOR) activity, providing a mechanism of autophagy induction. It was also dependent on the expression of RIP-1 kinase (discussed below) and cylindromatosis (turban tumour syndrome), which have been reported to be key regulators of necroptosis. Inhibition of RIP-1 and cylindromatosis restored glucocorticoid resistance completely.
Necrostatin and inhibition of cell death
In their characterization of this novel cell death pathway Degterev and coworkers [7] were aided substantially by the use of a small tryptophan-based compound, they termed necrostatin-1 (Nec-1).
Nec-1 was identified following the screening of a chemical library of some 15,000 compounds for inhibitors of necrotic cell death induced by TNF-␣ in the presence of zVAD.fmk. Significantly, the drug was found to inhibit necrosis mediated through DR mobilization in the presence of caspase inhibition in all previously
described cellular models of necrosis [7] .
Thus, Nec-1 inhibited necrosis in (i) Jurkat cells treated with FasL, cycloheximide and zVAD.fmk, (ii) Jurkat cells expressing dimerizable FADD incubated with the dimerizer AP2017 and zVAD.fmk and (iii) BALB/c 3T3, SV40-transformed MEF, HT-29, IEC-18 and HL-60 cells treated with TNF-␣ and zVAD.fmk. It should be noted that in Jurkat cells treated with FasL/cyclohexamide/zVAD.fmk an inactive form of Nec-1, designated Nec-1i, failed to prevent cell death.
Focusing on the specificity of Nec-1, comparative studies were performed in which its effects on DR-induced apoptosis and necrosis were evaluated [7] . [7, [39] [40] [41] [42] . It has been suggested that some of these molecules could eventually find application as treatments in degenerative disease. Recently, it was proposed that necrostatins should be considered as representing key agents for confirming the presence of necroptosis in cells and tissues [42] .
Nec-1 was not found to influence FasL-/cyclohexamide-induced staining of cells with the fluorescent dyes (and markers of apoptosis) annexin-V and propidium iodide, indicating that apoptosis does not represent its cellular target. Further evidence that
Following on from the initial work of Degterev and colleagues [7] , it was reported that macrophage death induced by the plant sterol sitosterol, which underlies a condition called sitosterolemia and has been linked to premature atherosclerosis, was caspase independent and blocked by Nec-1 [43] As outlined earlier, PARP-1 has been implicated in necrosis [29] [30] [31] [32] [33] . In a study carried out by Hitomi and coworkers [54] ,
L929 cells treated with TNF-␣ and zVAD.fmk were screened for genes required for necroptosis. This resulted in the identification of 432 genes that regulate necroptosis, 32 genes that act downstream and/or function as modulators of RIP-1 kinase (see section below on RIP kinases), 32 genes that mediate DR-mediated apoptosis and 7 genes involved in apoptosis. In addition, PARP-2, which shares 60% homology with PARP-1 in the catalytic domain, was identified as being a gene required for necroptosis. Oligomerization of PARP-1 and PARP-2 stimulates PARP catalytic activity in promoting DNA repair. PARP-2 is cleaved in apoptosis but with a delayed time course relative to PARP-1, possibly indicating that PARP-2 is not the preferred substrate for caspases compared to PARP-1. The expression of a caspase-resistant form of PARP-1 has been found to promote necrosis [55], whereas activation of PARP-1 which results in NAD
ϩ hydrolysis has been suggested as a mechanism leading to reduced NAD ϩ levels and energy failure in necrosis [56] . The findings described led Hitomi et al. [54] 
to propose that when PARP-2 catalytic activity is elevated for sustained periods resistance to caspase action may occur resulting in necroptotic pathways being initiated. More recently, the role of PARP activation in necroptosis was examined in HT-22 cells [57]. It was demonstrated that PJ34, a potent and specific inhibitor of PARP, completely blocked oxidative stress-induced necroptosis. Interestingly, although Nec-1 was found to reduce PARP activity it did not influence PARP-1 expression in glutamate-treated cells or protect against cell death mediated by the PARP activator N-methyl-N I -nitro-N-nitrosoguanidine (MNNG). By contrast, PJ34 protected against MNNG cytotoxicity. From these studies it was concluded that Nec-1 is not a direct inhibitor of PARP-1 and that its site of action lies upstream of PARP.
Necroptosis, necrostatin and RIP-1 kinase
The RIPs are a family of serine/threonine kinases that function as sensors of cellular stress and mediate both survival and deathinducing cellular mechanisms [58] [59] [60] [61] . [58] [59] [60] [61] . [58] [59] [60] [61] .
These recruitment domains are responsible for directing the kinases to their appropriate signalling pathways. RIP-1 has been implicated in cell death associated with trauma such as stroke and myocardial infarction [42, 58-61] and studies in RIP-1-deficient mice have indicated that it represents a key factor determining cellular survival following exposure to stress signals [62]. It possesses a C-terminal death domain that is important for binding to DR such as TNF-receptor 1, TRAIL (TNF-related apoptosis-inducing ligand)-receptor 1 and TRAIL-receptor 2, and to the death domain-containing adaptor proteins such as TNF-receptorassociated death domain and FADD
Necrosis induced by TNF-␣ in T cells has been reported to be dependent on serine/threonine kinase activity associated with RIP-1 [63]. In another study focusing on the relative contributions made by apoptotic and non-apoptotic pathways to TNF-␣-induced cell death, non-apoptotic cell death was found to occur through a receptor-mediated process involving the activation of an intracellular signalling complex incorporating RIP-1 [64]. More recently, employing wild-type and RIP-deficient Jurkat cells, Degterev et al. [65] identified RIP-1 kinase as being the principal kinase involved in the activation of necroptosis and the primary target for the anti-necroptotic actions of the necrostatins. In the case of Nec-1 its actions on necroptosis were shown to relate specifically to its inhibitory effects on RIP-1 kinase activity (as indicated by RIP-1 autophosphorylation) and occurred in a concentration-dependent manner. Significantly, evidence was obtained that the inhibitory actions of Nec-1 focused on the activation segment (T loop) of RIP-1. Although two other necrostatins, namely Nec-3 and Nec-5, also targeted RIP-1 kinase, it was found that the inhibitory actions of these agents were mediated via mechanisms distinct from those modulated by Nec-1. Degterev et al. [65] concluded that their data indicated that the necrostatins represent the first-in-class inhibitors of RIP-1 kinase, which they suggested was the major upstream kinase involved in the mobilization of necroptosis.
Oxidative damage is a feature of many neurological conditions and recently Kim et al. [66] Vandenabeele et al. [68] 
have reviewed the evidence that the kinases RIP-1 and RIP-3 are involved in TNF-induced cell death, including necroptosis. These workers have suggested that the regulation of RIP-1 and RIP-3 and their downstream signalling pathways may represent therapeutic targets in conditions characterized by cellular destruction, such as I/R injury and neurodegeneration.
Necrostatin and tissue injury
A body of evidence now exists indicating that necrostatin protects against tissue injury induced by both chemical and physical insults. This evidence has implications for two of the principal causes of death, namely neurological and cardiovascular diseases.
Necrostatin and cerebrocortical injury
In the original study by Degterev et al. [7] [74] . Additionally, Nec-1 delayed the opening of the mitochondrial permeability transition pore (MPTP), a proposed key determinant of tissue injury, in rat cardiomyocytes [74] . In an in vivo murine study conducted by Chua et al. [75] [44, 45] H9c2 myoblasts Iodoacetate [46] Chinese hamster ovary K1 cells, Rainbow trout cells Cd [47, 49] HT-22 hippocampal cells Glutamic acid [50] Mouse cortical astrocytes Hemin [51] Rat cortical neurons NMDA [52] SH-SY5Y neuroblastoma cells Al [53] Oligodendrocyte precursors Arachidonic acid [66] T cells Anti-CD3 antibody, TNF-␣ [67] Mouse cerebral cortex (in vivo I/R model) Middle cerebral artery occlusion [7] Mouse forebrain, thalamus (in vivo HI model) Right common carotid ligation [69] Mouse cerebral cortex (in vivo model) CCI [70] ST14A striatal cells; zVAD-fmk [72] Mouse R6/2 in vivo HD model [73] 
Necrostatin and retinal injury
Concluding remarks
Without doubt the recent identification of necroptosis has generated considerable excitement and yielded important new information concerning the mechanisms underlying cell death. It has also provided us with a potential target for therapeutic manipulation in the context
Mouse cerebral cortex (in vivo I/R model); mouse cortical neurons (in vitro) Middle cerebral artery occlusion (in vivo); OGD (in vitro)
Murine myocardium (in vitro and in vivo I/R models); C2C12 and H9c2 myocytes Global ischemia (Langendorff isolated heart); LAD ligation (in vivo)
; peroxide (myocytes) [74] Murine myocardium (in vivo I/R model) LAD ligation [75, 76] Rat retina (in vivo I/R model) Intraocular pressure elevation [78] of degenerative disease. [40] .
